- $541.48m
- $629.63m
- €153.71m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.96 | ||
| Price to Tang. Book | 4.95 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.31 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.25% | ||
| Return on Equity | -58.29% | ||
| Operating Margin | -53.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 126.2 | 110.32 | 348.09 | 361.3 | 153.71 | 202.24 | 226.67 | 6.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Directors
- Frederic Grimaud CSU (57)
- Thomas Lingelbach CMG (58)
- Franck Grimaud PRE (54)
- James Sulat VSU (70)
- Peter Buhler CFO (51)
- Perry Celentano COO
- Andreas Meinke SVP
- Vincent Dequenne SVP
- Manfred Tiefenbacher VFN
- Gerald Strohmaier VPR
- Joshua Drumm VPR
- Jason Golan VPR
- Olivier Jankowitsch VPR
- Anna Ponten-engelhardt VPR
- Klaus Schwamborn VPR
- Frederic Jacotot GCN (57)
- Janet Hoogstraate MGB
- Juan Jaramillo MGB (50)
- Frances Muir MGB
- Anne-Marie Graffin IND (60)
- Johanna Pattenier IND (61)
- Sharon Tetlow IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 24th, 1999
- Public Since
- June 28th, 2007
- No. of Employees
- 684
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 138,787,820
- Address
- 6 rue Alain Bombard, SAINT-HERBLAIN, 44800
- Web
- https://valneva.com/
- Phone
- +33 228073710
- Auditors
- Deloitte & Associes
Similar to VALN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:23 UTC, shares in Valneva SE are trading at $7.58. This share price information is delayed by 15 minutes.
Shares in Valneva SE last closed at $7.58 and the price had moved by -26.09% over the past 365 days. In terms of relative price strength the Valneva SE share price has underperformed the S&P500 Index by -38.49% over the past year.
The overall consensus recommendation for Valneva SE is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Valneva SE does not currently pay a dividend.
Valneva SE does not currently pay a dividend.
Valneva SE does not currently pay a dividend.
To buy shares in Valneva SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $7.58, shares in Valneva SE had a market capitalisation of $541.48m.
Here are the trading details for Valneva SE:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: VALN
Based on an overall assessment of its quality, value and momentum Valneva SE is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Valneva SE is $18.05. That is 138% above the last closing price of $7.58.
Analysts covering Valneva SE currently have a consensus Earnings Per Share (EPS) forecast of -€0.14 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Valneva SE. Over the past six months, its share price has underperformed the S&P500 Index by -39.26%.
As of the last closing price of $7.58, shares in Valneva SE were trading -31.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Valneva SE PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Valneva SE's management team is headed by:
- Frederic Grimaud - CSU
- Thomas Lingelbach - CMG
- Franck Grimaud - PRE
- James Sulat - VSU
- Peter Buhler - CFO
- Perry Celentano - COO
- Andreas Meinke - SVP
- Vincent Dequenne - SVP
- Manfred Tiefenbacher - VFN
- Gerald Strohmaier - VPR
- Joshua Drumm - VPR
- Jason Golan - VPR
- Olivier Jankowitsch - VPR
- Anna Ponten-engelhardt - VPR
- Klaus Schwamborn - VPR
- Frederic Jacotot - GCN
- Janet Hoogstraate - MGB
- Juan Jaramillo - MGB
- Frances Muir - MGB
- Anne-Marie Graffin - IND
- Johanna Pattenier - IND
- Sharon Tetlow - IND